Search
for
Sort by
Research 241–270 of 1000+
- Anthralin/dithranol in dermatology
- Dermatological adverse events with taxane chemotherapy
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
- Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
- Severe cutaneous adverse reactions to drugs
- Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database
- Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database
- Reporting on Adverse Clinical Events
- Signal Mining for Non-Bleeding Adverse Event in Novel Oral Anticoagulants: A Pharmacovigilance Study Based on the FAERS Database
- FDA Reports of Alopecia as an Adverse Event to Isotretinoin
- The pharmacovigilance analysis of adverse events of erlotinib based on the open access FAERS database
- Spontaneous cutaneous adverse drug reaction reports—An analysis of a 10‐year dataset in Singapore
- Impact of Reporter Type on Signal Detection of Cancer Therapy-Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System
- Dupilumab‐associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study
- Differences in reproductive toxicology between alopecia drugs: an analysis on adverse events among female and male cases
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital
- Management of Serious Adverse Events Following Deoxycholic Acid Injection for Submental and Jowl Fat Reduction: A Systematic Review and Management Recommendations
- Adverse Cutaneous Reactions to Antidepressants
- Severe hair loss associated with psyc hotropic drugs in psychiatric inpatients—Data from an observational pharmacovigilance program in German-speaking countries
- Impact of Reporter Type on Signal Detection of Cancer Therapy–Induced Alopecia: A Hypothesis-Generating Study Using the FDA Adverse Event Reporting System
- Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
- Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Adverse Events Associated with Azathioprine Treatment in Korean Pediatric Inflammatory Bowel Disease Patients
- Adverse Events in Isotretinoin Therapy: A Single-Arm Meta-Analysis
- Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System (FAERS) With a Focus on Pericardial Effusions
- Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025
- 329 Mechanisms of Cutaneous Adverse Events during Targeted Cancer Therapy